GE HealthCare Technologies Inc. research snapshot
GEHC AI stock analysis currently reads GE HealthCare Technologies Inc. as a scaled medical technology company with a large installed base, recurring service and software touchpoints, and defensible positions in imaging, advanced visualization, patient care, and pharmaceutical diagnostics. The July 8, 2026 signal is balanced rather than aggressive: FY2025 revenue rose 4.8% to $20.625 billion, FY2025 net income attributable to GE HealthCare was $2.084 billion, Q1 2026 revenue rose 7.4% to $5.131 billion, and backlog was $21.8 billion, but Q1 margin was hurt by tariffs, a PDx supplier issue, PCS weakness, and higher input costs. At $64.89 and about $29.52 billion in market value, GEHC trades near 15.6x TTM EPS and 19.7x free cash flow per share, which gives some valuation support but still requires steady execution. This page is informational research and not investment advice.
Current price
$64.89
Market cap
$29.52 billion
AI score
67 / 100
Rating
Durable medical technology franchise with moderate valuation support and execution risk from inflation, tariffs, and segment margin pressure
Trend status
Mixed technical trend, with price near the 50-day average, below the 200-day average in StockAnalysis data, and neutral RSI
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | GE HealthCare sells mission-critical imaging systems, diagnostics, monitoring, visualization software, and services into hospitals and healthcare networks, with a large installed base and FY2025 revenue of $20.625 billion. | High |
| Moat | The moat comes from installed equipment, regulatory approvals, service relationships, hospital workflow integration, brand trust, clinical data, and product breadth rather than a pure network effect. | Medium-high |
| Management | CEO Peter Arduini has led GE HealthCare since the spinoff and previously ran Integra LifeSciences. Management has focused on precision care, margin actions, tuck-in acquisitions, dividends, and buybacks. | Medium-high |
| Financial trend | FY2025 revenue rose 4.8%, organic orders rose 5.2%, free cash flow was $1.5 billion, and Q1 2026 revenue rose 7.4%, but Q1 adjusted EBIT margin fell to 13.5%. | High |
| Valuation | At $64.89, GEHC trades near 15.6x TTM EPS, 2.8x book value, 19.7x free cash flow per share, and 1.4x sales, a lower multiple than premium medtech but not a deep distress price. | Medium-high |
| Technical trend | Technical signals are mixed: RSI is near neutral, price is close to the 50-day average, and broader moving-average readings conflict across sources. | Medium |
| Risk level | Main risks are hospital capital spending cycles, China demand, tariffs, inflation, supplier issues, reimbursement pressure, cybersecurity, product quality, debt, and Intelerad integration. | Medium-high |
| AI confidence | Descriptive confidence is high because official filings and multiple data sources agree. Return confidence is lower because margin recovery and multiple expansion are not guaranteed. | High data confidence |
| Investment certainty | Investment certainty is medium. GEHC has a real franchise, but the thesis needs evidence of sustained organic order growth and margin repair after the Q1 2026 reset. | Medium |
GEHC AI stock forecast
The GEHC AI stock forecast uses scenario math around the $64.89 data cutoff price. It does not claim that AI can predict a precise future stock price. The audited three-year model produced a bullish anchor near $94.60, a base anchor near $70.40, and a bearish anchor near $45.70 before dividends, using TTM EPS of $4.17 and scenario multiples. These anchors are valuation scenarios, not guaranteed targets.
$90 to $98
More likely if organic revenue growth stays positive, backlog converts cleanly, pricing offsets tariffs and inflation, PCS margins recover, Intelerad strengthens enterprise imaging, and investors re-rate GEHC toward a higher-quality medtech multiple.
$66 to $74
More likely if GEHC grows EPS at a low-single-digit to mid-single-digit pace, keeps free cash flow above $1.4 billion, reduces inflation drag gradually, and trades near a mid-teens earnings multiple.
$44 to $48
More likely if hospital capital spending weakens, China remains soft, tariff and supplier costs persist, PCS pressure spreads, debt limits flexibility, or the market assigns a lower multiple to slow medtech growth.
GEHC AI technical analysis
GEHC AI technical analysis is mixed as of the July 8, 2026 cutoff. StockAnalysis showed market cap near $29.52 billion, a 50-day moving average of $63.51, a 200-day moving average of $73.98, RSI of 52.59, and average 20-day volume of about 4.85 million shares. Investing.com showed RSI near 49.35, MACD slightly positive, the 50-day average near $64.94, and the 200-day average near $63.89. Because sources differ on moving-average timing, live chart confirmation matters before using any setup.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $64.89 | Current market reference used for the July 8, 2026 market-cap and valuation math. |
| Immediate support | $63.50 to $64.95 | This band is anchored to the 50-day moving averages cited by StockAnalysis and Investing.com. |
| Secondary support | $60.68 to $61.00 | Intellectia cited $60.68 as a strong support level, making the low $60s a key risk-control zone. |
| Major support | $57.85 to $59.50 | The next Fibonacci floor near $57.865 and a cited 52-week range low near $59.49 define a deeper thesis-review area. |
| Near resistance | $66.36 to $67.20 | A break above immediate resistance and the 60-day moving-average area would improve the short-term setup. |
| Major resistance | $73.98 to $75.01 | The 200-day moving-average area is the main medium-term resistance zone in StockAnalysis and Intellectia snapshots. |
| Moving averages | Near 50-day, below or near 200-day depending on source | StockAnalysis showed price below the 200-day average, while Investing.com showed a 200-day average near the current price. This conflict lowers technical confidence. |
| Momentum | RSI 49 to 53, MACD slightly positive | Momentum is neutral rather than overbought, with a mild positive MACD signal in one public technical snapshot. |
| Volume | About 4.85 million average 20-day shares | GEHC is liquid enough for most public-market analysis, but breakouts should be confirmed by volume. |
| Volatility | 52-week price change about -14.7% | GEHC has lagged despite positive revenue growth, which shows that margin and guidance revisions matter to the stock. |
| Invalidation | Close below $60.68, then below $57.85 | A sustained break under the low-$60s would weaken the medium-term setup and force a review of margin, order, and debt assumptions. |
GEHC AI trading strategy
The GEHC AI trading strategy below is a rules-based framework, not personalized financial advice. It combines backlog, order growth, margin repair, valuation, technical confirmation, and explicit invalidation levels.
Watch for GEHC to hold the $63.50 to $64.95 support band, reclaim $66.36 to $67.20, and then approach the $74 to $75 200-day area while Q2 2026 results confirm backlog conversion and margin repair.
A close below $60.68 should reduce confidence. A close below $57.85 would shift the setup from trend-following to thesis review.
If GEHC pulls back toward the high $50s without a break in orders, free cash flow, or adjusted EPS guidance, compare the reset price with the base scenario near $70.40 and the bearish scenario near $45.70.
Do not average down only because the multiple looks lower than premium medtech. Require evidence that Q1 margin pressure was temporary and that pricing actions are working.
Track Q2 2026 earnings, organic orders, book-to-bill, backlog, adjusted EBIT margin, PCS performance, China demand, tariff mitigation, free cash flow, debt, Intelerad integration, and product-quality signals.
Lower the rating if organic demand slows while debt remains elevated or if margin recovery keeps moving out beyond 2026.
Investment research summary
Customers pay GE HealthCare because hospitals need reliable imaging, diagnostics, monitoring, visualization, workflow software, service, and uptime for clinical decisions and patient throughput.
The moat is strongest in installed equipment, regulated product lines, service contracts, clinical workflow integration, hospital relationships, brand trust, and scale purchasing. It is weaker where hardware replacement cycles are slow or procurement pressure is high.
The thesis can fail if hospital capital spending slows, China demand remains weak, tariffs and inflation overwhelm pricing, product quality issues rise, cybersecurity risk damages trust, or debt-funded acquisitions dilute returns.
Peter Arduini has medtech operating experience and has led GE HealthCare since the spinoff. Management is trying to use the Heartbeat operating system, targeted M&A, buybacks, and dividends while navigating tariff and input-cost pressure.
GEHC sits in long-duration healthcare needs: imaging, diagnostics, AI-assisted workflow, cloud enterprise imaging, and hospital productivity. The trend is durable, but not immune to budget cycles, regulation, and reimbursement pressure.
At roughly 15.6x TTM EPS and 19.7x free cash flow per share, GEHC offers more valuation support than high-growth medtech, but the margin of safety depends on organic growth, cash conversion, and a credible path back to better margins.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| GEHC quote reference | $64.89 current market data reference on July 8, 2026 | StockAnalysis statistics and public quote snapshots | July 8, 2026 |
| Market capitalization verification | $29.52 billion calculated from $64.89 x 454.89 million shares, compared with reported market cap near $29.65 billion | Pineify financial_rigor.py and StockAnalysis statistics | July 8, 2026 |
| Shares outstanding | 454.89 million shares in StockAnalysis, compared with 455.75 million shares outstanding as of January 28, 2026 in the 2025 Form 10-K | StockAnalysis and GEHC 2025 Form 10-K | July 8, 2026 |
| FY2025 revenue | $20.625 billion, up 4.8%; cross-validated with StockAnalysis and Macrotrends at $20.625 billion | GE HealthCare FY2025 results and 2025 Form 10-K | July 8, 2026 |
| FY2025 net income attributable to GE HealthCare | $2.084 billion in the 2025 Form 10-K, cross-validated with Macrotrends | GEHC 2025 Form 10-K and Macrotrends | July 8, 2026 |
| FY2025 cash flow | $2.0 billion operating cash flow and $1.5 billion free cash flow; capital expenditures were $482 million | GE HealthCare FY2025 results | July 8, 2026 |
| Q1 2026 revenue and backlog | $5.131 billion revenue, up 7.4%; organic orders up 1.1%; book-to-bill 1.07x; backlog $21.8 billion | GE HealthCare Q1 2026 earnings release | July 8, 2026 |
| Q1 2026 cash and debt | $2.3 billion cash and equivalents, $3.5 billion revolving credit access, and $10.1 billion total debt outstanding | GE HealthCare Q1 2026 earnings release | July 8, 2026 |
| FY2025 segment revenue | Imaging $10.010 billion, AVS $5.353 billion, PCS $3.086 billion, and PDx $2.900 billion | GEHC 2025 Form 10-K segment tables | July 8, 2026 |
| Valuation ratios | PE 15.56, forward PE 13.03, PS 1.41, PB 2.77, P/FCF 19.43, EV/Sales 1.80, and EV/EBITDA 10.74 | StockAnalysis statistics | July 8, 2026 |
| Technical indicators | StockAnalysis showed 50-day average $63.51, 200-day average $73.98, RSI 52.59, and average 20-day volume 4.85 million shares | StockAnalysis statistics | July 8, 2026 |
| Additional technical snapshot | Investing.com showed RSI 49.353, MACD 0.020, 50-day average $64.94, and 200-day average $63.89 | Investing.com technical analysis | July 8, 2026 |
This GEHC AI stock analysis page is an informational research tool only. It is not investment advice, financial planning, or a recommendation to buy, sell, short, or hold GE HealthCare Technologies Inc. Forecast scenarios are based on available public data and simplified assumptions as of July 8, 2026, and they can be wrong. Always verify current filings, prices, liquidity, tax rules, and personal risk constraints before making investment decisions.
